Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer

Breast Cancer Research and Treatment

Volumn 58, Issue 2, 1999, Pages 157-162

  Robertson, J F R ^a   Howell, A ^b   Buzdar, A ^c   Von Euler, M ^c   Lee, D ^d  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Anastrozole; Breast cancer; Static disease

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; MEGESTROL ACETATE;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; EUROPE; FEMALE; HUMANS; MEGESTROL ACETATE; NITRILES; POSTMENOPAUSE; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRIAZOLES; UNITED STATES;

EID: 0033403032     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006391902868     Document Type: Article

References (9)

1. 1. Robertson JFR, Williams MR, Todd J, Nicholson RI, Morgan DAL, Blamey RW: Factors predicting the response of patients with advanced breast cancer to endocrine (megace) therapy. Eur J Cancer Clin Oncol 25: 469-475, 1989
2. 2. Howell A, Mackintosh J, Jones M, Redford J, Wagstaff J, Sellwood RA: The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 24: 1567-1572, 1988
3. 3. Robertson JFR, Willsher PC, Cheung KL, Blamey RW: The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. Eur J Cancer 33: 1774-1779, 1997
4. 4. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV: Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in post-menopausal women with advanced breast cancer: Results of overview analysis of two phase II trials. J Clin Oncol 14: 2000-2011, 1996
5. 5. Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, Rubens RD: Assessment of response to therapy in advanced breast cancer. Eur J Cancer 13: 89-94, 1977
6. 6. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, Trunet PF: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double blind randomised trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16: 453-461, 1998
7. 7. Gershanovich M, Chaudri HA, Campos D, Lurie H, Bonaventura A, Jeffrey M, Buzzi F, Bodrogi L, Ludwig H, Reichardt P, O'Higgins N, Romieu G, Friederich P, Lassus M: Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethamide in postmenopausal women with advanced breast cancer. Ann Oncol 9: 639-645, 1998
8. 8. Goss PE, Winer EP, Tannock IF, Schwartz LH: Randomised phase III trial comprising the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. J Clin Oncol 17: 52-63, 1999
9. 9. Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel C, Eiermann W, Wolter J, Steinberg M, Webster A, Lee D: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. Cancer 83: 1142-1152, 1998